Quarterly Result15 Nov 2025, 10:34 pm
Sanjivani Paranteral Ltd Reports Strong Performance in Q2 FY26 Despite Challenges, Revenue Down 14.5% YoY
AI Summary
Sanjivani Paranteral Ltd, a Mumbai-based pharmaceutical company, reported a steady performance for the quarter ended 30th September 2025. Despite a 14.5% YoY decline in revenue to Rs. 155.0 mn, the company managed to maintain an EBITDA margin of 15.5%. The injectables segment showed strong growth, while the oral segment was impacted by shipment-related challenges due to macro uncertainties. The company is actively investing in R&D to expand its product portfolio and remains committed to its long-term strategy.
Key Highlights
- Revenue from operations declined by 14.5% YoY to Rs. 155.0 mn
- EBITDA margin stood at 15.5%
- Profit After Tax (PAT) stood at Rs. 16.4 mn, down 28.6% YoY
- Injectables segment reported strong growth
- Oral segment impacted by shipment-related challenges